brl 42810 has been researched along with Leprosy in 1 studies
Leprosy: A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Highleyman, L | 1 |
1 other study available for brl 42810 and Leprosy
| Article | Year |
|---|---|
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |